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Text: Background and objective: Regional volumetric studies have suggested that reversible brain
volume changes (pseudoatrophy) are mostly confined to the white matter, where inflammatory
infiltrates, glial activation and vasogenic oedema are more prominent compared to grey matter. The
aim of this study is to correlate pseudo-T2 values (a measure of brain hidratation status) with brain
volume changes in patients with clinically isolated syndrome (CIS).
Materials and methods: 96 patients with CIS were included (62 women; median age, 33 years;
age range, [19, 49]; EDSS mean, 2; EDSS range, [0, 4.5]; mean disease duration, 3.78 months).
Baseline and 12 months proton density (PD), T2-weighted, and 3D magnetization-prepared rapid
gradient-echo (MPRAGE) sequences were acquired on a 3.0T. The dual-echo sequence was used
to produce pseudo-T2 maps [pT2=(TE2-TE1)/ln(S1/S2)], where S1 and S2 were the measured
image intensities at each echo time, TE1 and TE2. Pseudo-T2 values, which are a simple measure
that reflects brain water content, were evaluated in regions of normal appearing white matter drawn
on PD-weighted images using Jim 6.0 software. The images acquired with the MPRAGE sequence
were used to obtain white and grey matter fractions using SIENAX (FSL). Changes between month
12 and baseline studies in pT2, white and grey matter fractions were then evaluated. Statistical
analysis include Spearman rank correlation test to evaluate the relation between changes in pT2 and
changes in white and grey matter fractions.
Results: A significant, although weak positive correlation (r=0.276, p=0.006) between changes in
pT2 and changes in white matter was found. Changes in grey matter did not correlate with changes
in pT2 (r=-0.002, p=0.982).
Conclusions: The results obtained support the concept that white matter volume changes in patients
with multiple sclerosis can be partially explained by fluctuations in brain water. Our results also
support the value of pseudo-T2 measures to assess white matter water changes, and its potential
role in distinguishing reversible from irreversible brain tissue loss (atrophy).
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